We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CORVax12

News List

OncoSec Announces First Subjects Dosed in Phase 1 Trial of COVID-19 Vaccine americanpharmaceuticalreview
January 28, 2021
OncoSec Medical Incorporated has dosed several subjects in its Phase 1 clinical trial of CORVax12, the only vaccine candidate to include an immunostimulatory cytokine to address COVID-19.
OncoSec Announces FDA Clearance for Trial of COVID-19 Vaccine Candidate americanpharmaceuticalreview
November 09, 2020
OncoSec Medical announced the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for a first-in-human Phase 1 trial for CORVax12, a novel DNA-encodable vaccine against SARS-CoV-2 that the Company ...
FDA approves first-in-human trial of COVID-19 vaccine candidate europeanpharmaceuticalreview
November 02, 2020
The safety and immunogenicity of CORVax12, a novel DNA-encodable COVID-19 vaccine, will be evaluated in 36 healthy volunteers.
OncoSec Collaborates with Providence Cancer Institute contractpharma
April 08, 2020
To conduct first-in-human trial of OncoSec's CORVax12, an investigational vaccine to prevent COVID-19.